LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Liguang Wang, Xue Chen, Xiaojiao Li, Yu Wang, Rong Shen · 2026
Read LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer by Liguang Wang, Xue Chen, Xiaojiao Li, Yu Wang, Rong Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13588105.txt.
Description
Liguang Wang and co-authors identify a driver of drug resistance in breast cancer in this 2026 paper. Everolimus is approved for hormone receptor positive, HER2 negative breast cancer. Many tumors stop responding to it, for reasons that were unclear. The team grew patient derived organoids, small tumor models, in sensitive and resistant forms.
Gene reading showed the gene LRRC32 was turned up sharply in resistant organoids. Forcing the gene on in sensitive cells cut cell death and raised survival. Turning it down in resistant cells did the opposite. It also stalled the cell cycle at the first growth phase. The findings mark LRRC32 as both a resistance driver and a possible drug target.
Catalog record
| CREATOR | Liguang Wang, Xue Chen, Xiaojiao Li, Yu Wang, Rong Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |